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The Iwiming effect of glueJtgon-like peptide-I (7-36) amide (GLP-I (7-36) amide), glucose-dependent insulin-releasing 
polypeptide (GIP) and cboi~ystokinin-8 (CCK-8) on glucose-induced insulin secretion from rat pancreas was investi- 
gated. The isolated pancreas was perfused in vitro with Krebs-Ringer bicarbonate buffer containing 2.8 mmol/I glucose. 
After 10 rain this medium was supplemented with GLP-I (7-36) amide, GIP or CCK-8 (10, 100, 1000 pmol/l) for 10 
rain. After an additional 10 rain period with 2.8 retool/! glucose alone, insulin secretion was stimulated with buffer 
containing 10 mmol/I glucose for 44 rain. In control experiments the typical biphasic insulin response to 10 mmol/i 
glucose occurred. Pretreatment of the pancreas with GIP augmented insulin secretion: 10 pmol/! GIP enhanced only 
the first phase of the secretory response to 10 mmol/I glucose; 100 and 1000 pmol/I GIP stimulated both phases of 
hormone secretion. After exposure to CCK-8, enhanced insulin release during the first (at 10 and 1000 pmol/! CCK-8) 
and the second phase (at 1000 pmol/l) was observed. Priming with 100 pmol/I GLP-I (7-36) amide significantly 
amplified the first and 1000 pmol/I GLP.I (7-36) umide both secretion periods. 10 pmol/! GLP-I (7-36) antide had no 
significant effect An three pepttde hormones influenced the first, quickly arising secretory response more than the 
second phase. Priming with forskolin (30 raM) enhanced the secretory response to 10 mM glucose plus 0.5 nM GLP-I 
(7-36) amlde &fold, With a glucose-responsive B-cell line (HIT cells), we investigated the hypothesis that the priming 
oJfeet d GLP-I (7-36)umlde is mediated by the adenylate cydase system. Priming with either IBMX (0.1 mM) or 
forskdin (2.5 F ~  eulmaeed the insulin release after a consecutive glucose stimulation (5 mM). This effect was 
iaenelmeed when GLP.I (7-36) am|de (100 pM) was added during glucose stimulation. Priming capacities of intestinal 
pelgide hommnes may be involved in the regulation of postgrandial insulin release. The incretin action of these 
bommnes can probably, at least in part, be explained by these effects. The priming effect of GLP-I (7-36) amide is 
most likely mediated by the adenylate eyclase system. 
Introduetion 
Insulin secretion from pancreatic beta cells is regu- 
lated by metabolic substrates, neurotransmitters and 
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36)amide; GIP, gluoose-dependent insulin-releasing polypeptide; 
CCK-8, cholecystokinin; IBMX, 3-isobutyimethyixanthi~. 
Correspondence (present address): H.C. Fehmann, Laboratory of 
Molecular Endocrinology, Wellman Building 3, Massachusetts Gen- 
eral Hospital, Harvard Medical School, Boston, MA 02114, U.S.A. 
gastrointestinal hormones. Glucose represents the most 
powerful stimulator of insulin release [1,2]. 
It is well established that prior exposure to glucose 
sensitizes the endocrine pancreas to a subsequent glu- 
cose stimulus [3-7]. This 'memory' for a previous glu- 
cose stimulation was shown to be both time and dose- 
dependently. It was observed in several species, includ- 
ing man [3-10], and there is no evidence that the islet 
memory described for glucose is due to the release of 
intestinal peptides and subsequent effects on the beta 
cell. 
Accumulating evidence suggests that several intesti- 
nal hormones are involved in the entero-insulinar axis 
[1,2]. The insulinotropic action of glucose-dependent 
insulin-releasing polypeptide (GIP) is known [11] and in 
recent studies glucagon-like peptide-1 (7-36) amide 
(GLP-1 (7-36) amide), a product of the posttranslatonal 
processing of proglucagon, was suggested as an even 
more effective incretin candidate [12-18]. It fulfills the 
classic conditions that allow identification as incretin 
hormone: it is released from the gut by nutrients, espe- 
cially carbohydrates [14], and it stimulates insulin secre- 
tion in the presence of elevated blood glucose levels 
[12-18]. 
In recent reports, Zawalich et al. [20] described a 
sensitizing effect of high concentrations of CCK on 
isolated islets, speculating that this action may play a 
role in a postulated incretin activity of CCK. This 
concept was supported by recent data demonstrating a 
change of the beta-cell responsiveness during systemic 
infusion of CCK [211. In addition, such a priming 
action on pancreatic beta-cells was shown for carbachol 
[22,23]. In the ease of CCK-priming, an enhanced 
turnover of membrane phosphoinositides is thought to 
be responsible for the change in beta-cell sensitivity to a 
subsequent glucose stimulation [20]. 
The present study was performed to explore the 
possible sensitizing effect of the most important incretin 
factors, GIP, GLP-1 (7-36) amide and CCK on the 
glucose-induced insulin secretion from perfused rat pan- 
crea~. In addition, experiments with forskolin and IBMX 
using the perfused rat pancreas and a glucose-respon- 
sive beta-cell line (HIT-T-15) were performed to study 
the mechansims involved in GLP-1 priming. 
Materials and Methods 
Materials. Synthetic glucagon-like peptide-1 (7-36) 
amide, CCK-8 (sulphated) and GIP were purchased 
from Peninsula (St. Helens, Merseyside, U.K.). Bovine 
serum albumin (fraction V) was from Serva (Heidel- 
berg, F.R.G.), aprotinin (Trasylol) from Bayer (Lever- 
kusen, F.R.G.), IBMX and forskolin from Sigma 
(Mti~chen, F.R.G.). All other chemicals used were ana- 
lytical grade and were purchased from Merck (Darms- 
tadt, F.R.G.). 
Animals. Male albino Wistar rats (180-240 g), kept 
in a light- and temperature-controlled room, were fed a 
standard diet (Altromin, Lage, F.R.G.) and had access 
to water ad libitum. 
Tissue culture. HIT-T-15 cells (obtained at passage 59 
from American Type Culture Collection, RockviUe, MD, 
U.S.A.) were grown in Ham's F12 K medium (87.5% 
v/v) supplemented with fetal bovine serum (2.5% v/v), 
dialyzed horse serum (10% v/v), 100 U/ml  penicillin 
and 10/Lg/ml streptomycin (all from Gibco, Eggen- 
stein, F.R.G.) in an 95% 02/5% CO2 humidified atmo- 
sphere at 37 ° C. Cells from passages 63-68 were used. 
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Perfusion experiments. Rats were anesthetized by an 
intraperitoneal injection of pentobarbitone sodium (45 
mg/kg body weight). The pancreas, spleen, stomach 
and proximal part of the duodenum were perfused 
through cannulated abdominal aorta and coeliac axis as 
described before [24]. The enthe preparation was re- 
moved from the cadaver and placed into a perfusion 
chamber (37 ° C) The perfusion media consisted of a 
Krebs-Ringer bicarbonate buffer (pH 7.40 when gassed 
with 95% O 2 and 5% CO2) which contained sodium 143 
retool/l, potassium 5.9 retool/l, calcium 2.5 retool/l, 
magnesium 1.18 retool/l, phosphate 1.2 mmol/l, sulfate 
1.2 retool/l, carbonate 25 mmol/l, chloride 127 retool/l, 
bicarbonate 25 mmol/l  and 0.2% bovine serum al- 
bumin. Venous effluent was collected on aprotinin (1000 
U/vial) in intervals by a canula inserted into the portal 
vein. The perfusion pumps were adjusted to generate a 
constant flow rate of 5 ml/min. One perfusion experi- 
ment lasted for 74 min. 
Experimental protocol 
Perfusion experiments (Fig. 1). After a basal period at 
2.8 mmol/l glucose for equilibration (10 min, I) the 
pancreas was perfused with medium containing 2.8 
mmol/l  glucose plus the peptide hormones for 10 min 
(control experiments without peptides, II) and then 10 
min with buffer at basal conditions (2.8 mmol/l glu- 
cose, III). Finally, insulin secretion was stimulated with 
10 retool/1 glucose for 44 min (0-8 min, IV; 9-44 min, 
V). 
Static incubation expe, imemz. After trypsinization 
about 106 cells (quantitated by a modified Neubauer- 
hemocytometer) were incubated for 60 min in Eppen- 
doff tubes in 1 ml Krebs-Ringer bicarbonate buffer (as 
described above) supplemented with 0.2% bovine serum 
albumin in the absence of glucose. Then the medium 
was changed to buffer containing IBMX (0.1 mmol/l), 
forskolin (2.5 pM) or GLP-1 (7-36) amide (100 pmol/l). 
After this priming period (10 rain), cells were main- 
tained for 10 min in Krebs-Ringer bicarbonate buffer. 
Subsequently insulin secretion was stimulated for 30 
rain with glucose, GLP-1 (7-36) amide and IBMX as 
described in Table IV. Insulin was determined in the 
entire supernatant after concentration using a vacuum 
centrifuge. Each medium change and an additional 
washing step were performed by mild centrifugation 
(1200 rpm, 2 min) and aspiration of the supernatant. 
IBMX and forskolin were dissolved in ethanol, resulting 
in a final concentration of 0.1% (v/v). 
Analytical determinations. Insulin was measured by 
radioimmunoassay [2~]. The standard was a mixture of 
rat insulin I and II (Novo, Mainz, F.R.G.; perfusion 
experiments) and pork insulin (Sigma, Miinchen, 
F.R.G.; HIT cell studies). The sensitivity of the assay 
was 0.25 ng/ml, the interassay variance 2.6%, and the 
intraassay variance 6.8%. 
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Fig, 1. Experimental protocols. After an equilibration period at basal conditions (2.8 mmol/! glucose, I) pancreata were perfused with medium 
containing 2.8 mmol/l glucose plus the peptides (control experiments without hormones; II) and then again with basal glucose (II1). Subsequently, 
insulin release was stimulated by 10 mmol/! glucose. Insulin release was determined as secretion rates of the first (ng insulin/0-8 min; IV) and the 
second phase (n8 insulin/9-44 rain; I/) of the biphasic insulin secretion pattern from the isolated perfused rat pancreas. Integrated secretion values 
were also determined for phases l -IIL 
Statistics. Insulin secretion from the isolated perfused 
rat pancreas is expressed as ng insulin/min (Figs. 2-4) 
and as integrated hormone release during phases I -V 
(I-IH: ng insulin/10 min, IV: ng insulin/8 min, V: ng 
insulin] 44 rain; tables I-III). Insulin secretion from 
static incubated HIT-T-15 cells was calculated as in- 
sulin release/30 rain per 106 cells; Table IV). Data are 
given as mean ±S.E.M. of (n) determinations. Statisti- 
cad analysis was performed by the U-test (perfusion 
experiments) and Student's t-test for unpaired data 




After peffusion of pancreata with medium containing 
10 mmol/l glucose, the typical biphasic insulin response 
occurred (phase 1, corresponding to IV, and phase 2 to 
V in Fig. 1) with a 6-8-fold higher hormone release 
above basal values (Figs. 2 - 4 ) .  
Exposure of the pancreas to CCK-8 (10, 100, 1000 
pmol/l) for 10 rain evoked an enhanced insulin secre- 
tory response to 10 mmol/l glucose (Fig. 2, Table I). 
Even at a concentration of 10 pmol/l CCK-8 aug- 
mented significantly the first, quickly arisiag, insulin 
secretory response (145%; P < 0.05). The second phase 
was enhanced significantly by 1 nmol/l CCK-8 (166%; 
P < 0.05; Fig. 2, Table I). 
TABLE I 
Effect of priming with CCK.8 (10, 100, 100 pmol/I) on integrated 
glucose-induced (10 retool~I) insulin secretion from the isolated perfused 
rat pancreas. 
Phases I-V, see Experimental protocol, l: ng insulin/lO rain, lI: ng 
insulin/lO rain, lII: ng insulin/lO rain; IV: ng insulin/8 rain, V: ng 
insulin/44 min. 
CCK-8 - 10 100 1000 
(pmol/l) 20 6 7 7 
n 
I 12.7+ 1.0 12.7+ 3.2 14.4+ 3.2 15.4+ 1.1 
II 8.9+ 1.1 16.54- 1.7 15.0+ 2.2 5.9+ 2.3 
III 10.2+ 2.1 7.7+ 0.9 9.8 + 1.3 10.9+ 1.7 
IV 29.1+ 3.0 42.2+ 7.3* 34.9+ 7.0 63.8+ 19.9 * 
100% 145% 119% 219% 
V 205.9+31.3 236.1+45.7 224.7+53.3 311.9+59.3" 
100% 115% 109% 166% 
* P < 0 .05 .  
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Fig. 2. Effect of priming with CCK-8 (10, 100, 1000 pmol/l) on glucose-induced insulin secretion from the isolated perfused rat pancreas. DeLailed 
data of these experiments are shown in Table I. Control, ® CCK-8 (pmol/l): 10, o; 100, B; 1000, z~. 
In a second group of experiments the priming capac- 
ity of GLP-1 (7-36) amide on glucose stimulated (10 
mmol/1) insulin secretion was studied. The results are 
shown in Fig. 3 and Table II. GLP-1 (7-36) amide 
induced a concentration-dependent (10 pmol/l :  126%, 
n.s.; 100 pmol/ l :  297~, P < 0.05:1000 pmol/l :  484%, 
P < 0.05) augmentation of insulin secretion during the 
first phase. The second period was significandy en- 
hanced by 1000 pmol / l  GLP-1 (7-36) amide (145%, 
P < 0.05), but not by 100 or 10 pmol / l  GLP-1 (107% 
and 117%; respectively). 
Since GIP represents another important incretin 
candidate, we investigated the possible sensitizing activ- 
ity of GIP on glucose-induced insulin secretion. After 
priming with all three GIP concentrations we found a 
significantly higher insulin release during the first secre- 
L . ~ .  2 6mM 91uc°se 
IRI (nglmin) I GLP-1 I 
T 
i 
10ram glucose ] 
10- 
Fig. 3. Effect of priming with GLP-1 (7-36) amide (10, 100, 1000 pmol/l) on glucose-induced insulin secretion from the isolated perfused rat 
pancreas. Detailed data of these experiments are shown in Table II. Control, ®. GLP-1 (7-36) amide (pmol/l): 10, o;  100, B; 1000, z~. 
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TABLE II 
Effect of priming with GLP-I (7-36) amide on integrated glacose-in- 
duced (10 mmol/l) insulin secretion from the isolated perfused rat 
pancreas. 
Phases I-V, see Experimental protocol. I: ng insulin/10 rain, II: ng 







10 100 1000 
6 5 5 
1 12.7+ 1.0 8.7+ 1.1 16,7+ 2.0 13.14. 2.0 
!! 8,9+ 1.1 12,6+ 0.6 15.1+ 3.1 16.2+ 2.1 
il1 ~0,2 + 2.1 8.5 + 0.4 16.6 4- 2.2 17.5 + 2.4 
IV 29.1 4. 3.0 36.1 + 8.1 86.5 4-14.2 * 140.9 + 136.0 * 
10070 12670 297% 484% 
V 205.9 4- 31.3 241.8 4. 61.7 220.2 + 27.4 299.0 4- 35.6 * 
10070 11770 107% 145% 
TABLE III 
Effect of GIP (10, 100, 1000 pmol/I) on glucose-induced (10 mmol/O 
insulin secretion from the isolated perfused rat pancreas 
Phases l-V, see Experimental protocol. I: ng insulin/10 min, II: ng 
insulin/10 min, Ill: ng insulin/10 min, IV: ng insulin/8 min, V: ng 
insulin/44 min. 
GIP - 10 100 I000 






12.7+ 1.0 16.34- 5.6 6.4+ 0.8 9.8± 2.0 
8.9+ 1.1 22.9+ 3.3 13.84. 1.1 19.9+ 4.6 
10.24- 2.1 13.0+ 1.2 8.64. 1.1 13.04. 1.3 
29.1+ 3.0 56.0+ 9.8* 119.2+ 7.5 126.8+29.0 * 
100% 192% 410% 43670 
205.9 4. 31.3 281.7 4. 35.2 348.1 4. 45.5 * 504.2 4. 96.8 * 
100% 137% 169% 24470 
* P < 0.05. 
* P < 0.05. 
tion phase (10 pmol/h 192%; P < 0.05; 100 pmol/l: 
410%, P < 0.05; 1000 pmol/h 436%, P < 0.05). The 
second period was positively modulated by 1000 pmol/1 
GIP (244%, P < 0.05). However, 10 and 100 pmol/1 
GIP had no significant effect. For detailed data see Fig. 
4 and Table III. 
At identical concentrations of hormones, GIP was 
more potent to aug,nent an insulin response to a subse- 
quent glucose stimulation than GLP-1 (7-36) amide. 10 
pmol/l GIP, but not 10 pmol/l GLP-1 (7-36) amide 
enhanced the first secretion period and 100 pmol/l  
GIP, but not 100 pmol/l GLP-1 (7-36) amide, ampli- 
fied the second phase. 
In comparison to GLP-1 (7-36) amide and GIP prim- 
ing with equimolar concentrations of CCK-8 exerted 
only moderate effects on glucose stimulated insulin 
release. When the effect of CCK-8 was studied insulin 
secretion values of approx. 50%, compared to corre- 
sponding experiments with GLP-1 (7-36) amide and 
GIP, were achieved. 
Priming with all three peptide hormones influenced 
both phases of glucose-induced insulin secretion in a 
different manner. Low concentrations of hormone in- 
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Fig. 4. Effect of priming ~ b  GIP (10, 100, 1000 pmol/l) on glucose-induced insulin secretion from the isolated perfused rat pancreas. Detailed 
d~ta of ~hese experiments are shown in Table III. Control, e. GIP (pmol/l): 10, o; 100, II; 1000, A. 
not the second, phase. When high hormone concentra- 
tions were utilized (1000 pmol/1) the quick, first insulin 
response to glucose was more enhanced than the re- 
sponse observed in the second, later phase (GIP: 436% 
vs. 244%; GLP-1 (7-36) amide: 484% vs. 145%; CCK-8: 
229% vs. 166%; Table I-III) .  
None of the tested peptides influenced the basal (2.8 
mmol/ l  glucose) insulin secretion (Figs. 2-4, Tables 
I-III). 
Perfusion of pancreata with forskolin (30 raM) in tae 
presence of 2.8 mM glucose doubled basal insulin re- 
lease (56,9 _+ 18.5 vs. 28.4 + 7.8 ng insulin/10 rain) and 
after a I0 rain washout period the secretory response to 
I0 mM glucose plus 0.5 nM GLP-I was markedly 
enhanced compared to the respective controls (no for- 
skolin pretreatment: first phase: 418.3 4-71.4 vs. 118.8 
4- 25.4 ng insulin/8 min; second phase: 2584.9 d: 510.8 
vs. 485.8 4- 53.9 ng insulin/44 min). 
H I T  cell studies (Table IV )  
Priming of HIT cells by IBMX (0.1 mM), forskolin 
(2.5 #M), or GLP-1 (7-36) amide (100 pM) resulted in a 
modest stimulation of insulin release when glucose con- 
centration was raised to 5 mM, This stimulatory effect 
was significantly increased when, after IBMX or for- 
TABLE IV 
Effect of priming with IBMX, forskolin and GLP-1 (7-36) amide ¢n 
insulin release from HIT cells. 
The cells were incubated for 10 min in buffer (without glucose) 
supplemented with 100 pM GLP-1 (7-36) amide, 0.1 mM IBMX or 
2.5 /~M forskolin. After a 10 min washout period, insulin secretion 
was stimulated for 30 min with glucose, GLP-1 (7-36) amide and 
IBMX as indicated. 
Priming period Stimulation period Insulin release n 
(ng/106 cells/ 
30 rain) 
1~ pM GL~I 
1~ pM GL~I 
0.1 mM IBMX 
0.1 mM IBMX 
2.5/tM forskolin 
2.5 p,M forskolin 
5 mM glucose 0.06 + 0.006 9 
10 mM glucose 0.08 + 0.015 4 
5 mM glucose 
+0.1 mM IBMX 0.605:0.021 * 6 
5 mM glucose + 
100 pM GLP-1 0.08 4.0.018 6 
5 mM glucose + 
2.5/tM forskolin 0.42-1-0.012 * 5 
5 mM glucose 0.17 + 0.014 * 6 
5 mM glucose + 
0.1 mM IBMX 0.67 + 0.070 * 6 
5 mM glucose 0.184-0.042 * 6 
5 mM glucose + 
100 pM GLP-1 0.25 4- 0.023 * 6 
5 mM glucose 0.12 4-0.004 * 6 
5 mM glucose+ 
100 pM GLP-1 0.57 4- 0.013 * 6 
* P < 0.05 compared to control experiments (no priming, 5 mM 
glucose); GLP-1 ffi GLP-1 (7-36) amide. 
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skolin priming, GLP-1 (7-36) amide was added at a 
concentration of 100 pM. At 100 pM, GLP-1 (7-36) 
amide exerted no significant stimulatory effect when the 
cells were studied without prior priming. When the cells 
were pretreated with GLP-1 (7-36) amide (100 pM), 
addition of IBMX (0.1 raM) potentiated the glucose-in- 
duced insulin release. However, this effect was not 
different compared with a sole IBMX-stimulation 
without prior priming. 
Discussion 
The acute and glucose-dependent insuhnotropic ac- 
tion of physiological concentrations of GIP and GLP-1 
(7-36) amide have been previously reported [11-18]. In 
rats CCK seems to stimulate the glucose-induced in- 
sulin secretion only in high, supraphysiological con- 
centrations [17,26,27] and in man endogenous and exog- 
enous CCK had no insulinotropic actixity [28,29]. On 
the other hand, physiological CCK levels potentiate the 
GIP-(30) and GLP-1 (7-36) amide-induced insulin 
secretion [17]. Therefore, the role of CCK in the entero- 
insulinar axis is not exactly defined. Data of the present 
study now suggest an additional indirect action of these 
incretin hormones at the pancreatic beta cell: short time 
exposure of the pancreas at nearly physiologic post- 
prandial concentrations to one of these peptides in- 
creased the respective insulin response to a subsequent 
glucose stimulation. Comparable to studies with CCK-8 
performed by Zawalich et al. [19,20], we observed a 
differential influence of such priming on biphasic in- 
sulin secretion pattern: all three peptide hormones en- 
hanced the first rapid response to glucose stimulation 
more than the second phase (Figs. 2-4, Table I-III) .  
This is of particular interest, since the first phase is 
thought to be more important in regulation of insulin 
efficacy than the second phase [31]. 
In the case of CCK-8 and GIP it was possible to 
demonstrate a priming effect of even 10 pmol/ l  of each 
peptide at the isolated perfused rat pancreas (Figs. 2, 4, 
Table I, III). Using isolated islets, Zawalich et al. [19l 
found no priming effect of CCK-8 in concentrations 
lower than 10 nmol / l  CCK-8. This discrepancy can be 
explained'by the use of different models (perfused pan- 
creas vs. collagenase isolated islets). It is known that 
islets isolated with collagenase method are more insensi- 
tive to various secretagogues than the isolated perfused 
gland [32]. 
Interestingly, we observed differences in the priming 
capacity between the three tested incretin hormones: 1 
nmol / l  GIP and GLP-1 (7-36) amide induced a 4-5-fold 
higher insulin secretion rate of the first phase and 1 
nmol/1 CCK-8 only doubled the quick-arising secretion 
period. 
On the other hand, 10 pmol / l  CCK-8 and GIP, but 
not 10 pmol/1 GLP-1 (7-36) amide, sensitized the beta 
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cells to the subsequent glucose stimulus. Therefore, it 
seems possible that CCK sensitizes insulin secretion in 
lower concentrations than GLP-1 (7-36) amide, but 
GLP-1 (7-36) amide and GIP are able to induce a 
stronger augmentation of glucose-induced insulin secre- 
tion after sensitizing. Since nutrients administered by 
the gastrointestinal route are more potent in enhancing 
insulin release than the same substances given directly 
intravascularly (the 'incretin effect'), these phenomena 
could represent very sensitive and elegant mechanisms 
in regulation of the adequate postprandial insulin re- 
sponse to prevent hypo- and hyperglycemia. 
Although the intracellular mechanism of glucose 
priming remains to be defined, some evidence to ex- 
plain the effects of gastrointestinal hormones exists 
which allows the construction of a working hypothesis. 
In the case of CCK, Zawalich et al. [20] suggested that 
the turnover of membrane phosphoinositides induced 
by CCK is largely responsible for the heightened status 
of secretory responsiveness to various stimuli of insulin 
release. Previously, we have shown that the GLP-1 
(7-36) amide-stimulated, glucose-induced insulin release 
is strongly potentiated by CCK [17]. Since the signal 
transmission after binding of GLP-1 (7-36) amide is 
adenylate-cyclase-linked [15,33,34], we have explained 
the CCK potentiation of the GLP-1 (7-36) amide effect 
by a synergistic interaction of the different second mes- 
senger systems as was suggested previously for the 
interaction of CCK and GIP [30]. Furthermore, an 
additive and not potentiated synergistic effect on the 
glucose-induced insulin secretion was reported when 
GLP-1 (7-36) amide and GIP were combined [18]. Since 
both hormones act via the adenylate cyclase system, the 
combination of both resulted in an additive effect on 
insulin release when submaximal, effective concentra- 
tions were used. From these results we speculate that 
the priming effect of GLP-1 (7-36) amide on the glu- 
¢me-induced insulin release is mediated by the adeny- 
late cyclase system. Previous experimental evidence ex- 
ists to support our hypothesis. 
It was earlier demonstrated, that IBMX exerts a 
priming effect upon rat pancreatic islets that results in a 
prompt enhancement of the insulin release in response 
to a subsequent stimulation [35]. After IBMX, the islets 
had a 'memory' for this preexposure that lasted at least 
30 rain [35]. Our data support these findings. Further- 
more, GLP-1 (7-36) amide potentiated the glucose-in- 
duced insulin secretion after IBMX or forskolin prim- 
ing. 
Since the GLP-1 (7-36) amide action relies on an 
activation of the adenylate cyclase system [34], these 
data argue in favor of an involvement of the adenylate 
cyclase system during GLP-1 (7-36) amide priming. 
Whereas IBMX enhances intracellular cAMP levels by 
an inhibition of the phosphodiesterase, which is re- 
sponsible for the cAMP degradation, forskolin directly 
activates the catalytic subunit of adenylate cyclase and 
thereby increases islet cAMP levels [36]. After forskolin 
priming the secretory response to glucose plus GLP-1 
from HIT ceils as well as from the perfused pancreas 
was much higher compared to the respective controls, 
which again argues in favour of an involvement of the 
adenylate cyclase system. 
It has been reported that cAMP negatively affects 
phosphoinositide turnover in different tissues [38,39]. If 
forskolin is added to the incubation medium of islets in 
the presence of 5.5 mM glucose, an amplified insulin 
secretory response results which is accompanied by a 
reduction of inositol phosphate accumulation [40]. Fur- 
thermore, GIP has been shown to increase islet cAMP 
levels and to reduce the stimulatory effect of CCK on 
Pl-hydrolysis, but to amplify insulin secretion [41]. 
When taken in their entirety, these results suggest 
that the priming effect of GLP-1 (7-36) amide and 
probably GIP is mediated by the adenylate cyclase 
system. Our data are consistent with the concept that a 
relationship between cAMP levels in the islets and the 
efficacy of other second messenger systems exists to 
stimulate insulin secretion. 
In conclusion, data of the present study indicate 
that: 
(1) priming with CCK-8, GIP or GLP-1 (7-36) amide 
sensitizes rat endocrine pancreas to a subsequent glu- 
cose stimulus; 
(2) this sensitizing effect is more pronounced for the 
first phase of the biphasic insulin secretion pattern; 
(3) low concentrations (10 pmol/l) of CCK-8 and GIP, 
but not of GLP-1 (7-36) amide induced a priming 
effect; 
(4) at higher concentrations (100 and 1000-prn~l/l) 
priming by GIP and GLP-1 (7-36) amide ismor_e~p0tent 
than priming by CCK-8; 
(5) the priming effects of GLP-1 (7-36) amide and 
probably GIP seem to be mediated by the adenylate 
cyclase system. 
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